Focus on Asthma Care

Back to articles

Lebrikizumab provides insights into interleukin-13 role in asthma

KEY POINT

Treatment with the experimental drug lebrikizumab, a humanized monoclonal antibody to interleukin-13, increased lung function in adults with asthma. Drug effects in the Phase II trial were greater in individuals with high levels of the protein periostin, which is secreted by bronchial epithelial cells in response to interleukin-13.

SOURCES

Corren J et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Aug 3. Epub ahead of print.